Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4973914 | 0.88 | GAA (0.47) | GAALMNAMAPTNPSR1PKM | |
| SCHEMBL6130353 | 0.86 | GAA (0.46) | GAALMNAMAPTNPSR1PKM | |
| SCHEMBL16118626 | 0.85 | GAA (0.44) | GAALMNAMAPTNPSR1PKM | |
| SCHEMBL1074030 | 0.78 | GAA (0.41) | GAALMNAMAPTNPSR1PKM | |
| SCHEMBL4889654 | 0.76 | EPHX2 (0.49) | EPHX2TSHR | |
| SCHEMBL4889651 | 0.76 | PKM (0.41) | GAALMNAMAPTNPSR1PKM | |
| SCHEMBL5608449 | 0.74 | GAA (0.38) | GAALMNAMAPTNPSR1PKM | |
| SCHEMBL5608314 | 0.74 | GAA (0.38) | GAALMNAMAPTNPSR1PKM | |
| SCHEMBL1073072 | 0.74 | GAA (0.41) | GAALMNAMAPTNPSR1PKM | |
| SCHEMBL11224012 | 0.73 | KDM4E (0.37) | GAAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275112-A1 | Invention Concerning Aminoadamantane Compounds | SCHREINER PETER R | 2008-11-06 | — | — | US | disclosed |
| US-20080275112-A1 | Invention Concerning Aminoadamantane Compounds | SCHREINER PETER R | 2008-11-06 | — | — | US | disclosed |
| US-20080275112-A1 | Invention Concerning Aminoadamantane Compounds | SCHREINER PETER R | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275112-A1 | Invention Concerning Aminoadamantane Compounds | GABRA5, GABRA1, GABRA4 | GAA 994/4885LMNA 3362/4885MAPT 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.